Aiforia establishes a subsidiary in France
Translation: Original published in Finnish on 7/10/2025 at 9:30 am EEST.
Aiforia has had a sales organization in France since 2023, and the newly formed subsidiary will strengthen the company's local presence and support its growing business in the country. The new subsidiary will support Aiforia's growth and customer service in France and enable closer cooperation with local healthcare providers than before. According to the company, interest in its AI-based solutions has grown significantly in recent years, as evidenced by the Paris and Nantes contracts. We believe the potential of these existing customers alone is significant if the expansion of customer partnerships is successful. France is investing heavily in the use of artificial intelligence in healthcare, and we expect Aiforia's business to expand significantly in France in the coming years. The launch of the subsidiary does not impact our view or the overall perception of the company, but we believe it bodes well for France's continued good progress in the future.
Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of areas from oncology to neuroscience. Aiforia Technologies is headquartered in Finland.
Read more on company pageKey Estimate Figures23.04
| 2024 | 25e | 26e | |
|---|---|---|---|
| Revenue | 2.9 | 4.7 | 7.6 |
| growth-% | 18.9 % | 65.7 % | 60.0 % |
| EBIT (adj.) | -12.2 | -11.9 | -12.0 |
| EBIT-% (adj.) | -427.8 % | -252.9 % | -158.1 % |
| EPS (adj.) | -0.41 | -0.37 | -0.38 |
| Dividend | 0.00 | 0.00 | 0.00 |
| Dividend % | |||
| P/E (adj.) | neg. | neg. | neg. |
| EV/EBITDA | neg. | neg. | neg. |